Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies

Bispecific Antibodies for Cancer Immunotherapy

(2010) Dafne Müller et al.   BIODRUGS

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

(2010) Diane Seimetz et al.   CANCER TREATMENT REVIEWS

Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects

(2010) Kannan Gunasekaran et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

(2010) Ralf Lutterbuese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†

(2010) Jonathan H. Davis et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

(2008) Judith Schmiedel et al.   CANCER CELL

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

(2008) M. Dechant et al.   CANCER RESEARCH

When binding is enough: nonactivating antibody formats

(2008) Aran F Labrijn et al.   CURRENT OPINION IN IMMUNOLOGY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE

Contribution of Variable Domains to the Stability of Humanized IgG1 Monoclonal Antibodies

(2007) Roxana M. Ionescu et al.   JOURNAL OF PHARMACEUTICAL SCIENCES